Phase 3
Completed N=78
Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function
Source: ClinicalTrials.gov NCT02795676 ↗Enrolled (actual)
78
Serious AEs
18.2%
Results posted
Aug 2023
Primary outcomePrimary: Annualized Change (Slope) in Estimated Glomerular Filtration Rate (eGFR) — -2.514; -2.155 mL/min/1.73 m^2/year
◆ Published Evidence
Established
43citations · ~22 / year
Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.
Summary
This was a randomized, double-blind, active control study of the enzyme replacement therapy (ERT) drug PRX-102 (pegunigalsidase alfa) in Fabry disease patients with impaired renal function. Patients who had been treated for approximately 1 year with agalsidase beta and who had been on a stable dose of that product for at least 6 months were randomized in a 2:1 ratio to either switch to PRX-102 or to continue treatment with agalsidase beta. Both treatments were delivered by intravenous infusions every two weeks, at a dosage of 1 mg/kg.
Linked Publications (2)
-
Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.
-
Health State Utility Values in Fabry Disease: Insights from the Pegunigalsidase Alfa Clinical Trials.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Annualized Change (Slope) in Estimated Glomerular Filtration Rate (eGFR) |
-2.514; -2.155 | — |
| SECONDARY Estimated Glomerular Filtration Rate (eGFR) |
73.45; 74.85; 69.35; 74.48; -2.39; -3.20 | — |
| SECONDARY Plasma Lyso-Gb3 |
15.20; 17.60; 18.80; 15.30; 1.15; -1.50 | — |
| SECONDARY Short Form Brief Pain Inventory (BPI) |
3.5; 2.6; 3.3; 3.0; -0.1; 0.6 | — |
| SECONDARY Mainz Severity Score Index (MSSI) |
23.18; 25.16; 22.11; 27.09; -2.07; 2.04 | — |
| SECONDARY Urine Protein/Creatinine Ratio (UPCR) |
69; 80; 76; 75; 17; 8 | — |
| SECONDARY Left Ventricular Mass Index With Hypertrophy at Baseline |
108.005; 103.030; 118.130; 121.380; -4.790; 4.120 | — |
| SECONDARY Left Ventricular Mass Index Without Hypertrophy at Baseline |
55.555; 66.040; 52.160; 62.520; 1.990; 0.515 | — |
Eligibility Criteria
Inclusion Criteria
- Symptomatic adult Fabry disease patients, age 18-60 years
- Males: Plasma and/or leucocyte alpha galactosidase activity (by activity assay) less than 30% mean normal levels and one or more of the characteristic features of Fabry disease
i. neuropathic pain
ii. cornea verticillata
iii. clustered angiokeratoma
- Females:
a. historical genetic test results consistent with Fabry pathogenic mutation and one or more of the described characteristic features of Fabry disease:
i. neuropathic pain
ii. cornea verticillata
iii. clustered angiokeratoma
b. or in the case of novel mutations a first degree male family member with Fabry disease with the same mutation, and one or more of the characteristic features of Fabry disease
i. neuropathic pain
ii. cornea verticillata
iii. clustered angiokeratoma
- Screening eGFR by CKD-EPI equation 40 to 120 mL/min/1.73 m²
- Linear negative slope of eGFR based on at least 3 serum creatinine values over approximately 1 year (range of 9 to 18 months, including the value obtained at the screening visit) of ≥ 2 mL/min/1.73 m²/year
- Treatment with a dose of 1 mg/kg agalsidase beta per infusion every 2 weeks for at least one year and at least 80% of 13 (10.4) mg/kg total dose over the last 6 months.
- Female patients and male patients whose co-partners are of child-bearing potential agree to use a medically accepted method of contraception, not including the rhythm method.
Exclusion Criteria
- History of anaphylaxis or Type 1 hypersensitivity reaction to agalsidase beta
- Known non-pathogenic Fabry mutations
- History of renal dialysis or transplantation
- History of acute kidney injury in the 12 months prior to screening, including specific kidney diseases (e.g., acute interstitial nephritis, acute glomerular and vasculitic renal diseases); non-specific conditions (e.g, ischemia, toxic injury); as well as extrarenal pathology (e.g., prerenal azotemia, and acute postrenal obstructive nephropathy)
- Angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy initiated or dose changed in the 4 weeks prior to screening
- Patient with a screening eGFR value between 91-120 mL/min/1.73 m², having an historical eGFR value higher than 120 mL/min/1.73 m² (during 9 to 18 months before screening)
- Urine protein to creatinine ratio (UPCR) > 0.5 g/g and not treated with an ACE inhibitor or ARB
- Cardiovascular event (myocardial infarction, unstable angina) in the 6 month period before randomization
- Congestive heart failure NYHA Class IV
- Cerebrovascular event (stroke, transient ischemic attack) in the 6 month period before randomization
- Known history of hypersensitivity to Gadolinium contrast agent that is not managed by the use of pre-medication
- Female subjects who are pregnant, planning to become pregnant during the study, or are breastfeeding
- Presence of any medical, emotional, behavioral or psychological condition that, in the judgment of the Investigator and/or Medical Director, would interfere with the patient's compliance with the requirements of the study
Data sourced from ClinicalTrials.gov (NCT02795676) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.